Ah Equity Partners Bio Ii, L.L Sells 5,000,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider directly owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Nautilus Biotechnology Price Performance

Shares of Nautilus Biotechnology stock opened at $2.39 on Friday. The firm has a market cap of $303.72 million, a P/E ratio of -5.20 and a beta of 0.75. The firm has a 50 day simple moving average of $2.86 and a 200 day simple moving average of $2.46. Nautilus Biotechnology, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NAUT shares. Guggenheim raised their price target on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC boosted its stake in Nautilus Biotechnology by 19.6% in the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after acquiring an additional 3,849 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in Nautilus Biotechnology by 4.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after acquiring an additional 5,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Nautilus Biotechnology by 2.2% in the first quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock valued at $1,031,000 after acquiring an additional 5,800 shares during the last quarter. Geode Capital Management LLC boosted its stake in Nautilus Biotechnology by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after acquiring an additional 7,307 shares during the last quarter. Finally, CTC Alternative Strategies Ltd. bought a new position in shares of Nautilus Biotechnology during the first quarter worth $48,000. 50.71% of the stock is owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.